drugset / Trial / NCT06761313

Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma

NCT06761313

Phase 4 Active not recruiting 40 enrolled Federal University of São Paulo
RandomizedParallel-groupSingle-blindTreatment

Summary

This project purpose is to evaluate the effectiveness, ocular surface quality, medication adherence and quality of life in 46 glaucoma patients in use of three separate drugs (Bimatoprost 0.3%, Timolol Maleate 0.5% and Brimonidine Tartrate 0.2%) comparing with triple combination, Triplenex. In this clinical trial approved by the Unifesp Etical and Research Comitte, volunteer glaucoma patients will be recruited from Unifesp Glaucoma Sector and VerMais Glaucoma Sector. They will be randomly divided em two groups,Group I is going to be treated with Triplenex (1 drop twice a day) and Grupo II with Brimonidine Tartarate (1 drop twice a day), Timolol Maleate (1 drop twice a day) and Bimatoprost (1 drop at night). At baseline visit a complete ophthalmolgical exam will be performed along with three questionnaires ("Ocular Surface Disease Index", "Glaucoma Treatment Compliance Assessment Tool" and "National Eye Institute Visual Function Questionnaire"),retinography, visual field, optic nerve OCT in all patients. This procedure will be repeated at baseline and within 4, 8, 12 weeks.

Timeline

Start
2021-03-01
Primary completion
2024-12-10
Completion
2025-02-26

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bimatoprost Other / unclassified 0.03 % Topical
Subject Bimatoprost Other / unclassified 0.3 % Topical
Subject Brimonidine Small molecule 0.2 % Topical
Subject Timolol Other / unclassified 0.5 % Topical

Indications